Zacks Investment Research
12 Dec 2025, 16:30 UTC · 46w ago
Verdict
Headline takes no side. We score ATRC +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
2 claims · scored −1 bearish … +1 bullish
AtriCure successfully treated the first patients using its new dual-energy platform combining Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation (RFA).
More positive than 75% of claims this week
AtriCure plans to initiate a clinical trial for the new dual-energy platform next year.
Continue reading
5 related stories
More positive than 47% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
Successful first-patient treatment with its new dual-energy platform validates a major innovation step and strengthens long-term growth outlook.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
+45.9%
Price agrees with the score
$60.41 vs $41.41 close before publication (Dec 11) · not market-adjusted
ATRC chart →
